Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $6.8 million.

  • Orchestra BioMed Holdings' Accumulated Expenses fell 280.07% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 280.07%. This contributed to the annual value of $6.1 million for FY2024, which is 1815.89% up from last year.
  • Orchestra BioMed Holdings' Accumulated Expenses amounted to $6.8 million in Q3 2025, which was down 280.07% from $6.6 million recorded in Q2 2025.
  • Orchestra BioMed Holdings' 5-year Accumulated Expenses high stood at $7.0 million for Q3 2024, and its period low was $202931.0 during Q1 2022.
  • Moreover, its 4-year median value for Accumulated Expenses was $4.3 million (2023), whereas its average is $4.3 million.
  • The largest annual percentage gain for Orchestra BioMed Holdings' Accumulated Expenses in the last 5 years was 150448.63% (2023), contrasted with its biggest fall of 422.25% (2023).
  • Quarter analysis of 4 years shows Orchestra BioMed Holdings' Accumulated Expenses stood at $5.4 million in 2022, then decreased by 4.22% to $5.1 million in 2023, then increased by 18.16% to $6.1 million in 2024, then increased by 12.38% to $6.8 million in 2025.
  • Its Accumulated Expenses stands at $6.8 million for Q3 2025, versus $6.6 million for Q2 2025 and $5.4 million for Q1 2025.